Cellular protein markers, therapeutics, and drug delivery strategies in the treatment of diabetes-associated liver fibrosis
Author:
Funder
National Institutes of Health
Publisher
Elsevier BV
Subject
Pharmaceutical Science
Reference180 articles.
1. Liver diseases: A major, neglected global public health problem requiring urgent actions and large-scale screening;Marcellin;Liver Int,2018
2. Burden of liver diseases in the world;Asrani;J Hepatol,2019
3. Epidemiology of non-alcoholic and alcoholic fatty liver diseases;Mitra;Transl Gastroenterol Hepatol,2020
4. Liver cirrhosis mortality in 187 countries between 1980 and 2010: a systematic analysis;Mokdad;BMC Med,2014
5. A round trip from nonalcoholic fatty liver disease to diabetes: molecular targets to the rescue?;Lonardo;Acta Diabetol,2019
Cited by 21 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. The effects of cGAS-STING inhibition in liver disease, kidney disease, and cellular senescence;Frontiers in Immunology;2024-07-24
2. Discovery of Novel Peptide Antagonists Targeting GPR55 for Liver Inflammation and Fibrosis;Journal of Medicinal Chemistry;2024-07-11
3. Prognostic Value of Fibrosis 4 (FIB-4) Index in Sepsis Patients;Journal of Personalized Medicine;2024-05-16
4. TET3 Regulates Hepatic Fibrosis in Mice through the Pyroptotic Pathway;J BIOL REG HOMEOS AG;2024
5. Intervention mechanism of marine-based chito-oligosaccharide on acute liver injury induced by AFB1 in rats;Bioresources and Bioprocessing;2024-01-18
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3